tetano
Editor, Senior Moderator
Vaccine
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.11.028 | How to Cite or Link Using DOI
Permissions & Reprints
Oral vaccination with inactivated influenza vaccine induces cross-protective immunity
Fu-Shi Quana, b, Richard W. Compansb, Corresponding Author Contact Information, E-mail The Corresponding Author, Sang-Moo Kangb, c, Corresponding Author Contact Information, E-mail The Corresponding Author
a Department of Biotechnology, Chungju National University, Jeungpyeong 368-701, South Korea
b Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA
c Center for Inflammation, Immunity & Infection, Department of Biology, Georgia State University, Atlanta, GA 30303, USA
Received 16 July 2011; revised 20 October 2011; Accepted 8 November 2011. Available online 19 November 2011.
Abstract
Oral vaccination would provide an easy and safe measure to prevent infectious diseases by facilitating mass immunization. We investigated the feasibility of oral vaccination with inactivated whole influenza virus (A/PR8/34). Oral vaccination of mice induced high levels of serum IgG and IgA antibodies specific to the homologous virus (A/PR8) as well as cross reactive to heterologous (A/California/04/09) and heterosubtypic viruses (A/Philippines/2/82). IgG1 isotype antibodies were found to be induced at significantly higher levels than IgG2a antibodies. These antibodies induced by oral vaccination exhibited hemagglutination inhibition activities. High levels of both IgG and IgA antibodies were induced in vagina and lungs. Mucosal IgA antibodies were also elicited in other sites including saliva, urine, and fecal samples. Orally vaccinated mice were completely protected against challenge with homologous or heterologous viruses, and partially protected against heterosubtypic virus. Importantly, high recall antibody secreting cell (ASC) responses were induced in spleen, indicating the generation of memory B cells by oral vaccination. The present study therefore presents new findings of cross-reactive antibodies at systemic and diverse mucosal sites, recall antibody responses, and cross-protective efficacies by oral vaccination, thus supporting a proof-of-concept that oral delivery of vaccines can be developed as an effective vaccination route.
Highlights
► We investigated cross protective efficacies of oral vaccination with the inactivated whole virus. ► This study presents that the antibodies induced by oral vaccination were found to be highly cross reactive. ► Oral vaccination could confer homotypic and heterotypic protective immunity. ► Oral vaccination with inactivated virus can induce memory B cells with capacity to rapidly respond upon a virus challenge.
http://www.sciencedirect.com/science/article/pii/S0264410X1101797X
In Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.11.028 | How to Cite or Link Using DOI
Permissions & Reprints
Oral vaccination with inactivated influenza vaccine induces cross-protective immunity
Fu-Shi Quana, b, Richard W. Compansb, Corresponding Author Contact Information, E-mail The Corresponding Author, Sang-Moo Kangb, c, Corresponding Author Contact Information, E-mail The Corresponding Author
a Department of Biotechnology, Chungju National University, Jeungpyeong 368-701, South Korea
b Department of Microbiology and Immunology, Emory Vaccine Center, Emory University School of Medicine, Atlanta, GA 30322, USA
c Center for Inflammation, Immunity & Infection, Department of Biology, Georgia State University, Atlanta, GA 30303, USA
Received 16 July 2011; revised 20 October 2011; Accepted 8 November 2011. Available online 19 November 2011.
Abstract
Oral vaccination would provide an easy and safe measure to prevent infectious diseases by facilitating mass immunization. We investigated the feasibility of oral vaccination with inactivated whole influenza virus (A/PR8/34). Oral vaccination of mice induced high levels of serum IgG and IgA antibodies specific to the homologous virus (A/PR8) as well as cross reactive to heterologous (A/California/04/09) and heterosubtypic viruses (A/Philippines/2/82). IgG1 isotype antibodies were found to be induced at significantly higher levels than IgG2a antibodies. These antibodies induced by oral vaccination exhibited hemagglutination inhibition activities. High levels of both IgG and IgA antibodies were induced in vagina and lungs. Mucosal IgA antibodies were also elicited in other sites including saliva, urine, and fecal samples. Orally vaccinated mice were completely protected against challenge with homologous or heterologous viruses, and partially protected against heterosubtypic virus. Importantly, high recall antibody secreting cell (ASC) responses were induced in spleen, indicating the generation of memory B cells by oral vaccination. The present study therefore presents new findings of cross-reactive antibodies at systemic and diverse mucosal sites, recall antibody responses, and cross-protective efficacies by oral vaccination, thus supporting a proof-of-concept that oral delivery of vaccines can be developed as an effective vaccination route.
Highlights
► We investigated cross protective efficacies of oral vaccination with the inactivated whole virus. ► This study presents that the antibodies induced by oral vaccination were found to be highly cross reactive. ► Oral vaccination could confer homotypic and heterotypic protective immunity. ► Oral vaccination with inactivated virus can induce memory B cells with capacity to rapidly respond upon a virus challenge.
http://www.sciencedirect.com/science/article/pii/S0264410X1101797X